No­vo Nordisk to buy PhI­II kid­ney dis­ease drug from Sin­ga­pore's KBP Bio­sciences

No­vo Nordisk will pay up to $1.3 bil­lion to buy a small mol­e­cule cur­rent­ly in Phase III for un­con­trolled hy­per­ten­sion and ad­vanced chron­ic kid­ney dis­ease as it looks to go up against Bay­er’s Keren­dia.

The Dan­ish be­he­moth, val­ued high­er than most oth­er Eu­ro­pean com­pa­nies thanks to a surge in de­mand for its di­a­betes and weight loss drugs, will ac­quire the treat­ment can­di­date from Sin­ga­pore biotech KBP Bio­sciences, the com­pa­nies said Mon­day morn­ing.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER